Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2024
Reporting Period: Event date November 8, 2024 (Board approval date October 29, 2024)
The Company, an emerging growth company incorporated in British Columbia, Canada, is reporting a material modification to the rights of security holders regarding a reverse stock consolidation.
Key Financial Metrics
This filing is a current report regarding a corporate action and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for these metrics.
Material Changes Versus Prior Period
- Share Consolidation: The Board approved a 1-for-20 reverse stock split (Consolidation) to regain compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum $1.00 bid price requirement.
- Share Count Reduction: Issued and outstanding Common Shares will be reduced from 14,361,550 to approximately 718,078 on a non-diluted basis.
- Ownership Percentage: Shareholders will maintain the same overall percentage of ownership post-Consolidation as held pre-Consolidation.
- Adjustments: Exercise prices and share counts for outstanding stock options, warrants, and convertible securities will be proportionately adjusted.
- Fractional Shares: Fractional shares less than half will be cancelled; those at least half will be rounded up to one whole share. No fractional shares will be issued.
Guidance, Outlook, and Management Commentary
- Effective Date: The Company anticipates Nasdaq will deem the Consolidation effective on November 14, 2024.
- Trading Resumption: Common Shares are expected to begin trading on a split-adjusted basis at the market open on November 15, 2024.
- Identification: The CUSIP number for the Common Shares will change to 457637700 immediately following the Consolidation.
- Risks/Contingencies: The primary driver is compliance with Nasdaq listing standards. The filing notes that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act.
Important Facts for Investor Verification
- Verify the exact number of shares held post-consolidation, accounting for the rounding rules for fractional shares (cancel if < 0.5, round up if ≥ 0.5).
- Confirm the adjusted exercise price and share count for any held stock options or warrants.
- Monitor the stock price on November 15, 2024, to ensure the bid price meets the $1.00 minimum requirement under the new share count.
- Update trading systems with the new CUSIP number (457637700) effective November 15, 2024.